Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

Figure 2

Relation between cytokine levels and B-cell frequency. (a) Two patients with systemic lupus erythematosus (SLE) (S5 and S14) representing the relation of B-cell frequency (left y-axis in diagrams) and cytokine levels (right y-axis) of BAFF (top row) and APRIL (bottom row) at B-cell-related time points. Dashed line depicts the cytokine level, and the unbroken line depicts the B-cell frequency. (b) Two patients with rheumatoid arthritis (RA) (R17 and R3) representing the relation of B-cell frequency (left y-axis) and levels of cytokines (right y-axis) BAFF (top row) and APRIL (bottom row) at baseline, depletion, and 6 months after treatment. APRIL, a proliferation-inducing ligand; BAFF, B-cell activation factor of the tumour necrosis factor family.

Back to article page